CLLS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

11.90M

-64.15%

-0.246

+44.51%

13.15M

+9.58%

-0.258

+43.06%

14.67M

-19.35%

-0.275

+14.58%

Estimates Revision

The market is revising Upward the revenue expectations for Cellectis S.A. (CLLS) for FY2025, with the revenue forecasts being adjusted by 52.58% over the past three months. During the same period, the stock price has changed by 4.19%.

Revenue Estimates for FY2025

Revise Upward

+52.58%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-12.91%

In Past 3 Month

Stock Price

Go Up

+4.19%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast CLLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLLS is 6.00 USD with a low forecast of 4.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

4.00

Averages

6.00

High

8.00

Current: 0.000

Low

4.00

Averages

6.00

High

8.00

Clear Street

Bill Maughan

initiated

2025-12-22

Reason

Clear Street

Bill Maughan

Price Target

2025-12-22

initiated

Reason

Clear Street analyst Bill Maughan initiated coverage of Cellectis with a Buy rating and $9 price target. Cellectis has produced "strong" efficacy data from its initial program, lasme-cel in acute lymphoblastic leukemia, and "an encouraging initial efficacy signal" from eti-cel in non-hodgkin's lymphoma, which the firm believes positions Cellectis well to be among the first companies to bring an allogenic CAR-T product for the treatment of hematological cancers to market.

Wells Fargo

Nick Abbott

Equal Weight

maintain

$3 -> $4

2025-10-20

Reason

Wells Fargo

Nick Abbott

Price Target

$3 -> $4

2025-10-20

maintain

Equal Weight

Reason

Wells Fargo analyst Nick Abbott raised the firm's price target on Cellectis to $4 from $3 and keeps an Equal Weight rating on the shares. The firm says new data from DL3 of ALL study are promising, with high CR/CRi & MRD-ve rates in patients with few options. Clarity on regulatory path is also positive, Wells adds. Pivotal Phase 2 execution is now key, with first data Q4 2026 and BLA filing in the second half of 2028, along with clarity on market size/opportunity.

Barclays

Gena Wang

maintain

$4 -> $8

2025-10-17

Reason

Barclays

Gena Wang

Price Target

$4 -> $8

2025-10-17

maintain

Reason

Barclays analyst Gena Wang raised the firm's price target on Cellectis to $8 from $4 and keeps an Overweight rating on the shares. The company's research and development day provided updates on lasme-cel's "promising" efficacy data, the analyst tells investors in a research note.

Barclays

Overweight

downgrade

$5 -> $4

2025-05-13

Reason

Barclays

Price Target

$5 -> $4

2025-05-13

downgrade

Overweight

Reason

Barclays lowered the firm's price target on Cellectis to $4 from $5 and keeps an Overweight rating on the shares. The company's Q1 was largely incremental with key pipeline programs on track, the analyst tells investors in a research note. The firm says Cellectis has a cash runway into the second half of 2027.

Valuation Metrics

The current forward P/E ratio for Cellectis SA (CLLS.O) is -4.69, compared to its 5-year average forward P/E of -1.91. For a more detailed relative valuation and DCF analysis to assess Cellectis SA 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.91

Current PE

-4.69

Overvalued PE

0.26

Undervalued PE

-4.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.70

Current EV/EBITDA

-4.43

Overvalued EV/EBITDA

-0.76

Undervalued EV/EBITDA

-4.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.36

Current PS

4.81

Overvalued PS

8.68

Undervalued PS

2.04

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CLLS News & Events

Events Timeline

No data

News

2.0

22:31 PMGlobenewswire

Cellectis Initiates Pivotal Trials for Lasme-cel and Eti-cel, 2026 Outlook Positive

7.5

01-06Newsfilter

Autolus Evaluates Cellares' Automated Platform for Manufacturing Expansion

6.0

2025-12-23Benzinga

Cellectis SA Receives Buy Rating with $9 Price Target from Clear Street

People Also Watch

Frequently Asked Questions

What is Cellectis SA (CLLS) stock price today?

The current price of CLLS is 4.48 USD — it has decreased -1.54 % in the last trading day.

What is Cellectis SA (CLLS)'s business?

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

What is the price predicton of CLLS Stock?

What is Cellectis SA (CLLS)'s revenue for the last quarter?

Cellectis SA revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is Cellectis SA (CLLS)'s earnings per share (EPS) for the last quarter?

Cellectis SA. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Cellectis SA (CLLS)'s fundamentals?

How many employees does Cellectis SA (CLLS). have?

Cellectis SA (CLLS) has 224 emplpoyees as of January 08 2026.

What is Cellectis SA (CLLS) market cap?

Today CLLS has the market capitalization of 449.46M USD.